Information Provided By: 
Fly News Breaks for June 18, 2018
CYTK
Jun 18, 2018 | 07:15 EDT
H.C. Wainwright analyst Joseph Pantginis raised his price target for Cytokinetics to $24 after the company announced Phase 2 study results using reldesemtiv in spinal muscular atrophy patients. The analyst says the data presented exceeded his expectations. He keeps a Buy rating on Cytokinetics.
News For CYTK From the Last 2 Days
CYTK
Apr 26, 2024 | 16:10 EDT
In a regulatory filing, Cytokinetics disclosed that on April 23, the company entered into an employment offer letter with Sung Lee, pursuant to which Lee has agreed to serve as the company's Executive Vice President, CFO, effective as of May 8. On the start date, Lee will assume the duties and responsibilities of the company's principal financial officer from Robert Blum, the company's President and CEO, who has been serving as the company's principal financial officer on an interim basis
